NAC (N-acetylcysteine)

N-acetylcysteine (NAC) is the stable form of the amino acid cysteine. It provides the limiting substrate the body needs to synthesize glutathione, its main intracellular antioxidant. It is the same molecule used as a mucolytic medication, although the regulatory framework is different: a medication with an authorized indication vs a food supplement. This page covers what it is, how it acts, the clinical evidence, the forms, the doses studied and safety.

What is N-acetylcysteine (NAC)?

N-acetylcysteine (NAC) is an N-acetylated derivative of the amino acid L-cysteine. Its chemical structure gives it greater stability and superior oral bioavailability compared with free cysteine, which makes it the most widely used form both in clinical medicine and in nutritional supplementation.

NAC's central contribution to the body is biochemical: it delivers cysteine to the cells, and cysteine is the limiting amino acid in the synthesis of glutathione, the main intracellular antioxidant. When the availability of intracellular cysteine is insufficient —something common in situations of elevated oxidative stress, aging or chronic disease— glutathione production is compromised. Supplementation with NAC can reverse this limitation.

There is also a second mechanism, independent of glutathione. The free thiol group (-SH) of NAC can neutralize free radicals directly, without first having to be converted into glutathione. This dual mechanism —glutathione precursor + direct antioxidant— is what distinguishes it from most of the available antioxidant compounds. To go deeper into the role of glutathione as an intracellular antioxidant, see the Glutathione page.

Chemical structure and why N-acetylation

Free cysteine is a chemically unstable amino acid: it oxidizes rapidly on contact with oxygen and forms cystine (its disulfide dimeric form), which has low intestinal absorption. N-acetylation —the addition of an acetyl group to the terminal nitrogen— protects the molecule during digestive transit and absorption, without altering the functionality of the thiol group responsible for its biological activity. After absorption, the body's enzymes remove the acetyl group and release functional cysteine.

NAC as a supplement and as a mucolytic medication: the same molecule, different regulatory framework

One of the most frequent questions about NAC is its relationship with the mucolytic medication that shares the same active ingredient. The short answer: it is exactly the same molecule. The active ingredient of that medication is N-acetylcysteine, chemically identical to the one used in food supplements.

What changes is the regulatory context:

• Mucolytic medication: authorized by the Spanish Agency for Medicines and Medical Devices (AEMPS) as a mucolytic (a fluidifier of bronchial secretions) in doses of 200, 600 or 100 mg. Authorization as a medication entails a specific regulatory process, with approved therapeutic indications and a detailed package leaflet. It is sold in pharmacies, without a medical prescription for the authorized indications.
• NAC supplement (food supplement): marketed under the regulatory framework of food supplements (Royal Decree 1487/2009). It has no authorized therapeutic indication; it is presented with functional statements associated with nutritional status and endogenous antioxidant defense, within the restrictions of Regulation (EC) 1924/2006.

The distinction is relevant: NAC as a supplement does not replace a medication authorized for a specific therapeutic indication. If a healthcare professional has prescribed that medication for a respiratory condition, NAC as a food supplement is not the appropriate alternative. Conversely, if what you are looking for is a nutritional contribution to support endogenous antioxidant defense, the supplement is the correct category.

Mechanism of action: how NAC raises glutathione

The relationship between NAC and glutathione is well characterized biochemically. Understanding this mechanism is essential to evaluate the available evidence.

Intracellular cysteine donor and glutathione precursor

After oral administration, NAC is absorbed in the small intestine and is deacetylated in plasma and tissues to release L-cysteine. The absolute oral bioavailability of NAC is modest due to extensive hepatic first-pass metabolism, but it is sufficient to raise the intracellular availability of cysteine in a sustained way with repeated doses.

Once inside the cell, cysteine enters the glutathione synthesis pathway, which occurs in two enzymatic steps:

• γ-glutamylcysteine synthetase (also called glutamate-cysteine ligase, GCL) joins glutamate and cysteine to form γ-glutamylcysteine. This is the rate-limiting step of synthesis.
• Glutathione synthetase adds glycine to complete the tripeptide glutathione (GSH).

Cysteine is the limiting substrate of this process: when its intracellular availability increases thanks to NAC, glutathione production increases.

Direct mucolytic action

The free thiol group of NAC can break the disulfide bridges of the mucoproteins present in bronchial secretions, reducing their viscosity. This is the mechanism that underpins the historical use of NAC as a mucolytic in mucolytic medications. The action is direct on the structure of the mucus and does not depend on glutathione synthesis.

Direct antioxidant, in addition to precursor

Independently of its conversion into glutathione, the free thiol group of NAC directly neutralizes reactive species such as the hydroxyl radical and peroxynitrite. This direct antioxidant effect is of lesser magnitude and duration than the one mediated by the sustained increase in glutathione, but it contributes to the overall biochemical profile of the compound.

Benefits of NAC according to the clinical evidence

Informative note: The information in this section is for educational purposes and is based on published scientific research. It does not constitute medical advice or a therapeutic recommendation. Always consult your doctor or pharmacist before starting any supplementation, especially if you have a health condition or take medication.

Research on NAC spans decades and multiple areas. The evidence is heterogeneous depending on the outcome studied, the dose, the duration and the population.

Oxidative stress and antioxidant capacity

This is the area with the most consistent evidence from a biochemical point of view. An authoritative review published in Current Opinion in Pharmacology analyzed the available evidence and concluded that supplementation with NAC reproducibly increases intracellular glutathione levels in multiple cell types, with documented effects in lymphocytes, hepatic cells and muscle cells.

The translation of this biochemical effect into broad clinical benefits in healthy people requires longer trials with defined clinical endpoints. The effect on biochemical markers is, however, a solid mechanistic basis for the research areas that follow.

Respiratory function and chronic obstructive pulmonary disease (COPD)

NAC was originally approved as a mucolytic, and its clinical use in respiratory conditions has been established for decades. The evidence on the prevention of exacerbations in COPD, however, is heterogeneous across trials:

• The BRONCUS trial, a 3-year randomized placebo-controlled clinical trial in 523 patients with COPD, found no significant differences in the frequency of exacerbations between the NAC group (600 mg/day) and the placebo group (1.25 vs 1.29 exacerbations/year, hazard ratio 0.99).
• The HIACE trial, a 1-year randomized placebo-controlled clinical trial in 120 patients with stable COPD, did find a significant reduction with NAC at a higher dose (600 mg twice a day): 0.96 exacerbations/year in the NAC group versus 1.71 in the placebo group.

The difference between the two results suggests that the dose (600 mg/day vs 1,200 mg/day) and possibly the characteristics of the population are relevant factors. The approved indications for this route require a medical prescription and form part of the clinical management of respiratory disease, not of the field of nutritional supplementation.

Liver and antidote in paracetamol poisoning (medical use)

Important note: The use of NAC as an antidote in paracetamol poisoning is a hospital emergency medical act. The information is included for purely educational purposes to contextualize the hepatoprotective role. It does not constitute a recommendation for use, nor can it be replaced by oral supplementation.

The most established use of NAC in clinical medicine is hepatic: it is the treatment of choice, intravenously, in acute paracetamol poisoning. It acts by replenishing the hepatic glutathione that the toxic metabolites of paracetamol have depleted. This hospital evidence of efficacy, supported by decades of clinical use, is the mechanistic basis of the association between hepatic glutathione and protection against oxidative damage in the liver.

The extrapolation of this hospital indication to oral supplementation in people without a diagnosed liver condition is limited and requires caution. Statements such as "detoxifies the liver" lack support in the peer-reviewed scientific literature as a claim applicable to healthy people.

GlyNAC and cellular health in older adults

The most recent interest in NAC in the context of cellular health comes from its combination with glycine (GlyNAC), based on the observation that both amino acids are limiting substrates of glutathione synthesis: cysteine (provided by NAC) in the first enzymatic step and glycine in the second.

A pilot clinical trial published in Clinical and Translational Medicine in 8 older adults (with a parallel group of 8 young adults) evaluated GlyNAC over 24 weeks and documented improvements in erythrocyte glutathione concentration, in oxidative stress markers, in mitochondrial function, in inflammation markers, in insulin sensitivity, in muscle strength and in walking speed. The effects diminished after 12 weeks of supplement withdrawal.

A subsequent trial by the same research group, published in the Journal of Gerontology, extended these findings in a randomized placebo-controlled design in 24 older adults (12 with GlyNAC, 12 with an isonitrogenous alanine placebo) over 16 weeks. The GlyNAC group showed improvements in glutathione deficiency, oxidative stress, mitochondrial dysfunction and inflammation, together with benefits in physical function.

Context of the evidence: the studies on GlyNAC have been carried out in small groups of older adults with markers of baseline glutathione deficiency. The results are consistent but require confirmation in larger and longer trials before they can be translated into general recommendations. Research in this field is in its early stages.

Forms and routes of administration

Oral NAC (capsules, tablets)

This is the most common form in supplementation. It allows precise dosing and the most studied posology. The typical ranges in clinical research are between 600 and 1,200 mg/day, usually divided into two intakes. Gastrointestinal tolerability improves when taken with a small amount of food, although optimal absorption is observed on a relatively empty stomach.

Effervescent NAC

The classic form of the mucolytic medication (in doses of 200 mg or 600 mg). The effervescent presentation may favor somewhat faster absorption than standard capsules, but it requires preparation in water and has a characteristic sulfurous odor that some people find unpleasant.

Intravenous NAC (medical use)

Important note: The intravenous administration of NAC is a hospital medical act that requires prescription and professional supervision. The information is included exclusively to contextualize the available evidence. It does not constitute a recommendation for use.

Intravenous administration bypasses the digestive barrier and allows high plasma concentrations to be reached. Hospital protocols use it as an antidote in paracetamol poisoning and, in research, in other specific clinical conditions. The oral and intravenous routes are not interchangeable: the magnitude and the temporal profile of the effect differ significantly.

Food sources and natural precursors

NAC as such is not found in significant amounts in foods —it is a stable synthetic form of cysteine—. What is present in the diet is free cysteine and, above all, its metabolic precursor: methionine.

Cysteine and methionine in the diet

The usual dietary sources of cysteine and methionine include eggs (especially the egg white), dairy products (cheese, yogurt), meat, fish, legumes (lentils, chickpeas), whole grains, seeds (sunflower, sesame, chia) and nuts. A diet with an adequate and varied protein intake covers the cysteine needs for the basal synthesis of glutathione in healthy people.

Why NAC and not free cysteine as a supplement

Free cysteine is chemically unstable and oxidizes rapidly to cystine, with lower intestinal absorption. N-acetylation protects the molecule and improves delivery to the cells. For this reason, supplements based on free cysteine are rare on the market, while NAC is the standard form both in research and in supplementation.

Doses studied in clinical trials

The doses of NAC used in clinical research vary depending on the objective. The documented ranges are listed below for informative purposes.

Table of oral doses documented in clinical research

The dose most frequently used in general supplementation studies ranges between 600 and 1,200 mg/day, usually divided into two intakes.

Important note: the doses mentioned correspond to those used in research. They do not constitute a dose recommendation. Consult your doctor or pharmacist before starting any supplementation.

Safety, side effects and interactions

NAC has a well-established safety profile thanks to decades of clinical use. Like any bioactive compound, its consumption is not without considerations.

Most frequent adverse effects

At the usual oral supplementation doses (600-1,200 mg/day), the reported adverse effects are generally mild and transient:

• Gastrointestinal discomfort: nausea, vomiting, diarrhea or abdominal pain. They are reduced by taking the supplement with a small amount of food.
• Characteristic sulfurous odor: the thiol group gives off an odor that can be perceived on the breath and in the urine. It has no clinical significance.
• Hypersensitivity reactions: infrequent with oral administration. More frequent with hospital intravenous administration.

Contraindications and precautions

• Bronchial asthma: NAC can cause bronchospasm in people with asthma, especially in inhalation formulations. With oral administration the risk is lower, but caution and prior medical consultation are recommended.
• Active peptic ulcer: NAC can irritate the gastric mucosa.
• Pregnancy and breastfeeding: there are insufficient data to recommend general supplementation during these stages. Its use in pregnancy has been carried out in specific clinical contexts under medical supervision, but this is not extrapolated to a food supplement.
• Children and adolescents: supplementation with NAC outside a medical indication is not recommended in these populations.

Relevant drug interactions

• Vasodilator nitrates (nitroglycerin and derivatives): NAC can potentiate the vasodilator effect and increase the risk of hypotension.
• Anticoagulants: possible interactions; consult the treating doctor if you take anticoagulation.
• Chemotherapy: people undergoing cancer treatment should consult their oncologist before any supplementation with antioxidant compounds.
• Activated charcoal: reduces the absorption of oral NAC; separate the intakes.

If you take regular medication or have any health condition, consult your doctor or pharmacist before starting supplementation with NAC.

How to choose a NAC supplement

The first criterion is to decide what you are looking for: if what you need is the mucolytic medication for a specific respiratory condition, the right thing to do is to turn to that medication after consulting your doctor or pharmacist. If what you are looking for is a nutritional contribution to support endogenous antioxidant defense, the NAC food supplement is the correct category.

To evaluate a NAC supplement with sound judgment:

• Dose per unit: supplementation studies have typically used 600 mg (often divided into two intakes of 300 mg). Capsules with significantly lower doses may require multiple intakes to reach the effective dose.
• Form of presentation: capsules or tablets for dosing precision; effervescent for somewhat faster absorption but with a pronounced sulfurous odor.
• Formulated synergies: products that combine NAC with preformed glutathione or with cofactors such as selenium (a substrate of glutathione peroxidase) may offer a more complete approach to the endogenous antioxidant system.
• Absence of unnecessary additives: avoid formulations with titanium dioxide, excess magnesium stearate, artificial colorings or unjustified excipients.
• Traceability and certifications: the manufacturer should offer batch traceability, certificates of analysis and, ideally, GMP certifications.

On the frequent question of taking oral glutathione instead of NAC: the oral bioavailability of preformed glutathione is debated because intestinal peptidases can hydrolyze the tripeptide. NAC, being a stable modified amino acid, is absorbed efficiently and crosses the cell membrane to feed glutathione synthesis in situ. The most complete formulation strategy combines both approaches.

NAC in the Pleniage portfolio

In the formulation of PLENIAGE® ANTIOX PRO, NAC (300 mg) is incorporated together with preformed glutathione (120 mg). This combination responds to a documented biochemical rationale: providing the precursor (cysteine via NAC) and the already-formed glutathione simultaneously, covering two complementary routes to support intracellular antioxidant defense. The product also includes other components of the antioxidant system (CoQ10, turmeric, pomegranate, astaxanthin, lutein, lycopene) that act in different cellular compartments.

This page is part of the Antioxidants and defenses cluster, where the molecules involved in cellular redox balance are explored in an integrated way. To go deeper into glutathione —the main intracellular antioxidant of which NAC is a precursor—, see the Glutathione page.

Frequently asked questions about NAC

Is supplement NAC the same as the one from the pharmacy?

Yes, it is exactly the same molecule (N-acetylcysteine). What changes is the regulatory context: the medication with this active ingredient is authorized as a mucolytic by the AEMPS, with specific therapeutic indications and a package leaflet. NAC as a food supplement is marketed under the supplement framework (Royal Decree 1487/2009), with no authorized therapeutic indication and with functional statements associated with nutritional status and endogenous antioxidant defense.

What is NAC used for?

As a supplement, NAC is used to support endogenous antioxidant defense, mainly as a precursor of glutathione, the main intracellular antioxidant. As a mucolytic medication, it has an authorized indication (it fluidifies bronchial secretions). These two uses belong to different regulatory categories and are not interchangeable.

What is the difference between taking NAC and taking glutathione directly?

NAC delivers cysteine to the cells so they can synthesize glutathione in situ. Oral preformed glutathione is a tripeptide that intestinal peptidases can hydrolyze, which limits its absorption. A formulation that combines NAC (precursor) with preformed glutathione covers both routes and is the most complete formulation strategy to support intracellular redox balance.

Can NAC be taken every day?

Clinical studies of oral NAC supplementation at 600-1,200 mg/day over weeks or months show a well-established safety profile in healthy adults. Very long-term safety data (more than 12 months) at doses above 1,200 mg/day are more limited. As with any supplement, consulting a healthcare professional before starting it is recommended, especially if you have medical conditions or take regular medication.

When is it best to take NAC, in the morning or at night?

There is no single recommendation. Study protocols usually split the dose into two intakes (morning and night) to keep plasma levels more stable. Gastrointestinal tolerability improves with a small amount of food, although optimal absorption occurs on a relatively empty stomach. The specific regimen depends on individual tolerability and on the goal.

Does NAC have any health claim approved by EFSA?

Currently, NAC does not have specific health claims approved by the European Food Safety Authority (EFSA) under Regulation (EC) 1924/2006 for use in food supplements. Manufacturers cannot attribute to it properties for the prevention or treatment of diseases on the label. Scientific research documents effects on biochemical markers and specific clinical areas (such as COPD in the context of the medication), but the regulatory approval of claims requires a specific level of evidence.

N-acetylcysteine is one of the best-studied compounds in the field of endogenous antioxidant defense. Its role as a precursor of glutathione —the body's main intracellular antioxidant— gives it a singular position in the supplementation landscape: it acts from inside the cell, where oxidative damage actually occurs. The clinical evidence supports its effect on biochemical markers of redox status; the translation into broad clinical benefits in healthy people requires longer trials with defined clinical endpoints. If you are interested in going deeper into strategies to support cellular redox balance, consult your doctor or pharmacist to assess whether supplementation is appropriate for your personal situation.

At PLENIAGE® we publish scientific content on evidence-based supplementation. You can explore the Antioxidants and defenses cluster for more pages and related articles.

---

References

The statements in the article are based on the available scientific literature. The key verified references that support the main claims about N-acetylcysteine, glutathione and endogenous antioxidant defense are listed below.

• Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine — a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355-9. PMID: 17602868.
• Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-9. PMID: 1362956.
• Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489-92. PMID: 14988435.
• Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417(1):1-13. PMID: 19061483.
• Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552-60. PMID: 15866309.
• Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106-118. PMID: 23348146.
• Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clin Transl Med. 2021;11(3):e372. PMID: 33783984.
• Kumar P, Liu C, Suliburk J, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89. PMID: 35975308.